Forest Laboratories, Inc. Announces Private Placement of Senior Notes
January 27 2014 - 7:00AM
Business Wire
Forest Laboratories, Inc. (NYSE:FRX) (“Forest Laboratories”)
today announced a proposed offering of $1.8 billion aggregate
principal amount of senior unsecured fixed rate notes in two
tranches, with one tranche due 2019 and the other tranche due 2021
(together, the “notes”). The precise timing, size, and terms of the
offering are subject to market conditions and other factors. Forest
Laboratories intends to use the net proceeds from the offering of
the notes, together with cash on hand, to fund its previously
announced proposed acquisition of Aptalis.
The notes initially will be sold in the United States to
qualified institutional buyers pursuant to Rule 144A under the
Securities Act of 1933, as amended (the "Securities Act"), and to
non-U.S. persons in accordance with Regulation S under the
Securities Act. The notes have not been registered under the
Securities Act or any state securities laws, and may not be offered
or sold in the United States absent registration or an applicable
exemption from registration requirements.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy the notes, nor shall it constitute
an offer, solicitation or sale in any jurisdiction in which, or to
any person to whom, such offer, solicitation or sale is unlawful.
Any offers of the notes will be made only by means of a private
offering memorandum.
About Forest Laboratories and Its Products
Forest Laboratories (NYSE:FRX) is a leading, fully integrated,
specialty pharmaceutical company largely focused on the United
States market. The Company markets a portfolio of branded drug
products and develops new medicines to treat patients suffering
from diseases principally in five therapeutic areas: central
nervous system, cardiovascular, gastrointestinal, respiratory, and
anti-infective. Our strategy of acquiring product rights for
development and commercialization through licensing, collaborative
partnerships and targeted mergers and acquisitions allows us to
take advantage of attractive late-stage development and commercial
opportunities, thereby managing the risks inherent in drug
development. The Company is headquartered in New York, NY.
This release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
These statements involve a number of risks and uncertainties,
including the difficulty of predicting FDA approvals, the
acceptance and demand for new pharmaceutical products, the impact
of competitive products and pricing, the timely development and
launch of new products, and the risk factors listed from time to
time in Forest Laboratories’ Annual Report on Form 10-K, Quarterly
Reports on Form 10-Q and any subsequent SEC filings. Forest assumes
no obligation to update forward-looking statements contained in
this release to reflect new information or future events or
developments.
Forest Laboratories, Inc.INVESTOR:Frank J. Murdolo,
1-212-224-6714Vice President – Investor RelationsorMEDIA:Amanda
KaufmanSenior Manager - Corporate Communications and Media
Relationsamanda.kaufman@frx.com
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Oct 2023 to Oct 2024